Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenamilast
- Development stage
- Preclinical
- Lead developer
- Transpire Bio
- Modality
- Small Molecules
- Administration
- Inhalation, Oral
01
Overview
Lenamilast (ITG-1052) is a small molecule phosphodiesterase 4 (PDE4) inhibitor specifically designed for the treatment of respiratory diseases. It acts by inhibiting PDE4, an enzyme involved in the inflammatory response, thereby reducing inflammation in respiratory tissues. Lenamilast is being developed for indications such as idiopathic pulmonary fibrosis and other respiratory conditions. The drug was originally developed by Suzhou IntraGrand Pharma and has been licensed to Transpire Bio for further development and commercialization in these indications[1][2][3][4].
- Brand names
- lenamilast
- Other names
- ITG-1052ITG1052ITG 1052
02
Targets
PDE4 (Phosphodiesterase 4A1)
Beyond the preview
Go deeper on lenamilast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenamilast.